Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sumitomo Dainippon Pharma Co ( (JP:4506) ) has issued an update.
Sumitomo Pharma Co., Ltd. announced details about its relationship with its parent company, Sumitomo Chemical Co., Ltd., which holds a 51.78% voting interest. The announcement highlights the company’s operational independence, despite its integration into the parent company’s corporate group. The collaboration includes joint ventures in regenerative medicine and shared resources, but the company maintains managerial independence, with no limitations imposed on its business activities by the parent company.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. is a core member of Sumitomo Chemical Co., Ltd.’s corporate group, focusing on the ethical drugs segment within the pharmaceutical industry. The company is involved in the development and commercialization of regenerative medicine and cell therapy products, and it collaborates closely with its parent company in various operational aspects, including leasing assets and procuring raw materials.
Average Trading Volume: 11,477,283
Technical Sentiment Signal: Buy
Current Market Cap: Yen372.3B
For an in-depth examination of 4506 stock, go to TipRanks’ Overview page.